United States - English - NLM (National Library of Medicine)

physicians total care, inc. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)] . clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and post-marketing experience (6.2)] - patients with narrow angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] . - patients with severe hypertension or severe coronary artery disease pregnancy category c: there are no adequate and well-controlled stu

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)]. clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and adverse reactions (6.2)] - patients with narrow-angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] - patients with severe hypertension or severe coronary artery disease risk summary the limited available data with clarinex-d 12 hour in pregnant wom

United Kingdom - English - myHealthbox

rosemont pharmaceuticals ltd - desloratadine - oral solution - 0.5mg/ml - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: - allergic rhinitis - urticaria

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - desloratadine - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - desloratadine - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - desloratadine - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lupin healthcare (uk - desloratadine - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - desloratadine - oral solution - 500microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - desloratadine - tablet - 5mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - desloratadine -